34th Annual Course Photo – Sept. 2019

35th Annual Offering of Critical Issues in Tumor Microenvironment: Angiogenesis, Metastasis and Immunology

October 26-29, 2020

Virtual Meeting

Lecture recordings will be available for 30 days after course ends.


Our 35th Annual Tumor Course will continue to offer the best in critical analysis of what is currently known about the tumor microenvironment, angiogenesis, metastasis, immunology, targeted therapies, metabolism, microbiome and a newly introduced topic, toxicity of immunotherapies. Our internationally recognized faculty will present their latest findings from their clinics and laboratories. The goal is to highlight key gaps in our present knowledge of cancer and outline future directions for research at the bench, in the clinic, and in drug development.

The course will continue its four-day live lecture format. The faculty will encourage open discussion and will provide critical comments on the challenges and the future opportunities in research on cancer and in establishment of novel therapy approaches and biomarkers to guide treatment.

The aim of this course is to analyze and synthesize the most up-to-date findings. Our faculty will present valuable information in a systematic and comprehensive framework, along with a critical review of various measurement techniques. This course is dedicated to helping to improve clinical translation of this knowledge and competence, leading to improved cancer treatment. Learning formats will include didactic lectures, Q&A and group case discussions.


The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credits™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.


Upon completion of our Critical Issues in Tumor Microenvironment course, participants will be able to:

*Evaluate molecularly targeted agents and immunotherapies approved or currently in clinical development for cancer treatment and incorporate into practice.
*Assess relevant, state-of-the-art or translational pre-clinical models of anti-cancer therapies.
*Recognize the steps and determinants of the metastatic process of cancer.
*Compare correlative studies of biomarkers and their response and resistance to targeted therapies in cancer patients.
*Evaluate state-of-the-art genetic and imaging techniques and their applications in pre-clinical and clinical studies.

Who Should Attend This Course?

The course is directed at physicians and researchers.


The course is designed to meet the following American Board of Medical Specialties (ABMS) / Accreditation Council for Continuing Medical Educational (ACCME) competencies: Medical Knowledge and Patient Care and Procedural Skills


The course is designed to meet the following Institute of Medicine (IOM) Competencies: Work in Interdisciplinary Teams, Employ Evidence-Based Practice, Apply Quality Improvement

Rakesh K. Jain, Ph.D., Andrew Werk Cook Professor of Tumor Biology, Harvard Medical School; Director, E.L. Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA